The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Use of Inhaled Corticosteroids and Risk of Fractures
Open accessAbstract
Treatment with systemic corticosteroids is known to increase the risk of fractures but little is known of the fracture risks associated with inhaled corticosteroids. A retrospective cohort study was conducted using a large UK primary care database (the General Practice Research Database [GPRD]). Inhaled corticosteroid users aged 18 years or older were compared with matched control patients and to a group of noncorticosteroid bronchodilator users. Patients with concomitant use of systemic corticosteroids were excluded. The study comprised 170,818 inhaled corticosteroid users, 108,786 bronchodilator users, and 170,818 control patients. The average age was 45.1 years in the inhaled corticosteroid, 49.3 years in the bronchodilator, and 45.2 years in the control groups. In the inhaled corticosteroid cohort, 54.5% were female. The relative rates (RRs) of nonvertebral, hip, and vertebral fractures during inhaled corticosteroid treatment compared with control were 1.15 (95% CI, 1.10–1.20), 1.22 (95% CI, 1.04–1.43), and 1.51 (95% CI, 1.22–1.85), respectively. No differences were found between the inhaled corticosteroid and bronchodilator groups (nonvertebral fracture RR = 1.00; 95% CI, 0.94–1.06). The rates of nonvertebral fractures among users of budesonide (RR = 0.95; 95% CI, 0.85–1.07) and fluticasone propionate (RR = 1.03; 95% CI, 0.71–1.49) were similar to the rate determined for users of beclomethasone dipropionate. We conclude that users of inhaled corticosteroids have an increased risk of fracture, particularly at the hip and spine. However, this excess risk may be related more to the underlying respiratory disease than to inhaled corticosteroid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Flexible regression models with cubic splines
Durrleman, S., & Simon, R. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080504 · Cited by 2,689
Modeling and variable selection in epidemiologic analysis
Greenland, S. (1989) · American Journal of Public Health · doi:10.2105/ajph.79.3.340 · Cited by 2,208
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Self-citationDose-Response and Trend Analysis in Epidemiology: Alternatives to Categorical Analysis
Greenland, S. (1995) · Epidemiology · doi:10.1097/00001648-199507000-00005 · Cited by 1,085
Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis
Lipworth, B. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.9.941 · Cited by 918 · cited 3×
“(4) In this study, there were 3311 (1.”
BackgroundJick, H., Jick, S. S., & Derby, L. E. (1991) · BMJ · doi:10.1136/bmj.302.6779.766 · Cited by 839
Statistical methods in cancer research
Gardner, B. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.1170 · Cited by 777
The crippling consequences of fractures and their impact on quality of life
Cooper, C. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)90022-x · Cited by 699
Self-citation
Cited by
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
Self-citationData Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Diagnosis of osteoporosis and assessment of fracture risk
Kanis, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08761-5 · Cited by 2,260
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
Self-citationPapaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
Self-citationFeng, X., & McDonald, J. M. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130203 · Cited by 1,272
Kanis, J. A., Borgstrom, F., De Laet, C., Johansson, H., Johnell, O., Jonsson, B., Oden, A., Zethraeus, N., Pfleger, B., & Khaltaev, N. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1780-5 · Cited by 1,233
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yang, Y.-X., Lewis, J. D., Epstein, S., & Metz, D. C. (2006) · JAMA · doi:10.1001/jama.296.24.2947 · Cited by 1,214
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886
Long-term side effects of glucocorticoids
Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H., & Foster, C. S. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1140743 · Cited by 869
Sgk1-Dependent Stimulation of Cardiac Na+/H+Exchanger Nhe1 by Dexamethasone
Voelkl, J., Pasham, V., Ahmed, M. S. E., Walker, B., Szteyn, K., Kuhl, D., Metzler, B., Alesutan, I., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350120 · Cited by 857
UK clinical guideline for the prevention and treatment of osteoporosis
The National Osteoporosis Guideline Group (NOGG), Compston, J., Cooper, A., Cooper, C., Gittoes, N., Gregson, C., Harvey, N., Hope, S., Kanis, J. A., McCloskey, E. V., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0324-5 · Cited by 826
Self-citationClinical Use of Bone Densitometry: Scientific Review
Cummings, S. R., Bates, D., & Black, D. M. (2002) · JAMA · doi:10.1001/jama.288.15.1889 · Cited by 817
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Rheumatology · doi:10.1093/rheumatology/39.12.1383 · Cited by 696
Self-citationGlucocorticoid-Induced Bone Disease
Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 694
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study
Richards, J., Rivadeneira, F., Inouye, M., Pastinen, T., Soranzo, N., Wilson, S., Andrew, T., Falchi, M., Gwilliam, R., Ahmadi, K., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60599-1 · Cited by 682
Psychiatric Adverse Effects of Corticosteroids
Warrington, T. P., & Bostwick, J. M. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.10.1361 · Cited by 611
Population‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis.
Staa, T. P. V., Geusens, P., Bijlsma, J. W. J., Leufkens, H. G. M., & Cooper, C. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22117 · Cited by 587
Self-citationBuckley, L., Guyatt, G., Fink, H. A., Cannon, M., Grossman, J., Hansen, K. E., Humphrey, M. B., Lane, N. E., Magrey, M., Miller, M., et al. (2017) · Arthritis Care & Research · doi:10.1002/acr.23279 · Cited by 579
Van Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11283 · Cited by 559
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Interpretation and use of FRAX in clinical practice
Task Force of the FRAX Initiative, Kanis, J. A., Hans, D., Cooper, C., Baim, S., Bilezikian, J. P., Binkley, N., Cauley, J. A., Compston, J. E., Dawson-Hughes, B., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1713-z · Cited by 532
Self-citationUse of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529
Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60250-6 · Cited by 527
Buckley, L., Guyatt, G., Fink, H. A., Cannon, M., Grossman, J., Hansen, K. E., Humphrey, M. B., Lane, N. E., Magrey, M., Miller, M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40137 · Cited by 527
Da Silva, J. A. P., Jacobs, J. W. G., Kirwan, J. R., Boers, M., Saag, K. G., Inês, L. B. S., de Koning, E. J. P., Buttgereit, F., Cutolo, M., Capell, H., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.038638 · Cited by 522
Wallach, S., Cohen, S., Reid, D. M., Hughes, R. A., Hosking, D. J., Laan, R. F., Doherty, S. M., Maricic, M., Rosen, C., Brown, J., et al. (2000) · Calcified Tissue International · doi:10.1007/s002230001146 · Cited by 513
Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493
Souverein, P. C., Berard, A., Van Staa, T. P., Cooper, C., Egberts, A. C. G., Leufkens, H. G. M., & Walker, B. R. (2004) · Heart · doi:10.1136/hrt.2003.020180 · Cited by 482
Self-citationHippisley-Cox, J., & Coupland, C. (2009) · BMJ · doi:10.1136/bmj.b4229 · Cited by 479
Glucocorticoid-induced osteoporosis: an update
Compston, J. (2018) · Endocrine · doi:10.1007/s12020-018-1588-2 · Cited by 471
Peacock, M., Turner, C. H., Econs, M. J., & Foroud, T. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0464 · Cited by 468
Use of proton pump inhibitors and risk of osteoporosis-related fractures
Targownik, L. E., Lix, L. M., Metge, C. J., Prior, H. J., Leung, S., & Leslie, W. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071330 · Cited by 436
Manolagas, S. C., & Parfitt, A. M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.010 · Cited by 404
Mechanisms of Glucocorticoid Action in Bone
CANALIS, E., & DELANY, A. M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04204.x · Cited by 406
The epidemiology of glucocorticoid-associated adverse events
McDonough, A. K., Curtis, J. R., & Saag, K. G. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f51031 · Cited by 405
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Determinants of Muscle and Bone Aging
Curtis, E., Litwic, A., Cooper, C., & Dennison, E. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25001 · Cited by 375
Self-citationEffect of Selective Serotonin Reuptake Inhibitors on the Risk of Fracture
Richards, J. B. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.2.188 · Cited by 386
Borer, K. T. (2005) · Sports Medicine · doi:10.2165/00007256-200535090-00004 · Cited by 373
Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M., & Pashos, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6908 · Cited by 366
Angeli, A., Guglielmi, G., Dovio, A., Capelli, G., de Feo, D., Giannini, S., Giorgino, R., Moro, L., & Giustina, A. (2006) · Bone · doi:10.1016/j.bone.2006.02.005 · Cited by 365
Glucocorticoid-Induced Osteoporosis and Osteonecrosis
Weinstein, R. S. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.004 · Cited by 364
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
Hippisley-Cox, J., & Coupland, C. (2012) · BMJ · doi:10.1136/bmj.e3427 · Cited by 351
Strehl, C., Bijlsma, J. W. J., de Wit, M., Boers, M., Caeyers, N., Cutolo, M., Dasgupta, B., Dixon, W. G., Geenen, R., Huizinga, T. W. J., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208916 · Cited by 340
Joint IOF-ECTS GIO Guidelines Working Group, Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., Cooper, C., Diez Perez, A., Eastell, R., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1958-1 · Cited by 335
Self-citationMANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management
Mirza, F., & Canalis, E. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0118 · Cited by 331
The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide
Curtis, E. M., Moon, R. J., Harvey, N. C., & Cooper, C. (2017) · Bone · doi:10.1016/j.bone.2017.01.024 · Cited by 330
Self-citationGuidance for the adjustment of FRAX according to the dose of glucocorticoids
Kanis, J. A., Johansson, H., Oden, A., & McCloskey, E. V. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1524-7 · Cited by 323
Secondary Causes of Osteoporosis
FITZPATRICK, L. A. (2002) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62214-3 · Cited by 311
Effects of inhaled glucocorticoids on bone density in premenopausal women.
Israel, E., Banerjee, T. R., Fitzmaurice, G. M., Kotlov, T. V., LaHive, K., & LeBoff, M. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002304 · Cited by 303
Glucocorticoid-induced osteoporosis
Briot, K., & Roux, C. (2015) · RMD Open · doi:10.1136/rmdopen-2014-000014 · Cited by 300
Fracture risk with intermittent high‐dose oral glucocorticoid therapy
De Vries, F., Bracke, M., Leufkens, H. G. M., Lammers, J. J., Cooper, C., & Van Staa, T. P. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22294 · Cited by 298
Self-citationOral glucocorticoid use is associated with an increased risk of fracture
Steinbuch, M., Youket, T. E., & Cohen, S. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1548-3 · Cited by 277
Use of Statins and Risk of Fractures
van Staa, T.-P. (2001) · JAMA · doi:10.1001/jama.285.14.1850 · Cited by 271
Self-citationManson, S. C., Brown, R. E., Cerulli, A., & Vidaurre, C. F. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.01.003 · Cited by 269
Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases
Hardy, R. S., Raza, K., & Cooper, M. S. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0371-y · Cited by 265
Drug-induced Osteoporosis: Mechanisms and Clinical Implications
Mazziotti, G., Canalis, E., & Giustina, A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.02.028 · Cited by 262
Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans
Womack, J. A., Goulet, J. L., Gibert, C., Brandt, C., Chang, C. C., Gulanski, B., Fraenkel, L., Mattocks, K., Rimland, D., Rodriguez-Barradas, M. C., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017217 · Cited by 261
The Pathogenesis, Epidemiology and Management of Glucocorticoid-Induced Osteoporosis
van Staa, T. P. (2006) · Calcified Tissue International · doi:10.1007/s00223-006-0019-1 · Cited by 260
Self-citationThe endothelium–bone axis in development, homeostasis and bone and joint disease
Tuckermann, J., & Adams, R. H. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00682-3 · Cited by 258
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Targownik, L. E., Lix, L. M., Leung, S., & Leslie, W. D. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.014 · Cited by 253
Exogenous cushing’s syndrome and glucocorticoid withdrawal
Hopkins, R. L., & Leinung, M. C. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.013 · Cited by 224
“A significant number of patients on long-term steroid therapy will have at least some loss of bone density [7,8], and oral and inhaled corticosteroid use are associated with increased bone fractures [9,10].”
BackgroundClinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry
Lewiecki, E. M., & Laster, A. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1178 · Cited by 201
Cooper, M. S., Rabbitt, E. H., Goddard, P. E., Bartlett, W. A., Hewison, M., & Stewart, P. M. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.979 · Cited by 200
11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Calcitonin Plays a Critical Role in Regulating Skeletal Mineral Metabolism during Lactation
Woodrow, J. P., Sharpe, C. J., Fudge, N. J., Hoff, A. O., Gagel, R. F., & Kovacs, C. S. (2006) · Endocrinology · doi:10.1210/en.2005-1616 · Cited by 195
Glucocorticoid induced autophagy in osteocytes
Xia, X., Kar, R., Gluhak-Heinrich, J., Yao, W., Lane, N. E., Bonewald, L. F., Biswas, S. K., Lo, W.-K., & Jiang, J. X. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.160 · Cited by 193
Glüer, C.-C., Marin, F., Ringe, J. D., Hawkins, F., Möricke, R., Papaioannu, N., Farahmand, P., Minisola, S., Martínez, G., Nolla, J. M., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1870 · Cited by 171
Glucocorticoids and bone: Local effects and systemic implications
Henneicke, H., Gasparini, S. J., Brennan-Speranza, T. C., Zhou, H., & Seibel, M. J. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.006 · Cited by 168
Kleiman, A., & Tuckermann, J. P. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.009 · Cited by 165
Mechanisms of glucocorticoid-induced osteoporosis.
Canalis, E. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00013 · Cited by 164
Risk of hip fracture in patients with a history of schizophrenia
Howard, L., Kirkwood, G., & Leese, M. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.023671 · Cited by 158
Pathogenic mechanisms of glucocorticoid-induced osteoporosis
Chen, M., Fu, W., Xu, H., & Liu, C.-J. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.002 · Cited by 146
STOCH, S. A., SAAG, K. G., GREENWALD, M., SEBBA, A. I., COHEN, S., VERBRUGGEN, N., GIEZEK, H., WEST, J., & SCHNITZER, T. J. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081207 · Cited by 100
Vestergaard, P., Jørgensen, J. O. L., Hagen, C., Hoeck, H. C., Laurberg, P., Rejnmark, L., Brixen, K., Weeke, J., Andersen, M., Conceicao, F. L., et al. (2002) · Clinical Endocrinology · doi:10.1046/j.0300-0664.2001.01464.x · Cited by 99
Effects of TZD use and discontinuation on fracture rates in ACCORD bone study
Schwartz, A. V., Chen, H., Ambrosius, W. T., Sood, A., Josse, R. G., Bonds, D. E., Schnall, A. M., Vittinghoff, E., Bauer, D. C., Banerji, M. A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1215 · Cited by 85
Understanding and managing corticosteroid-induced osteoporosis
Kobza, A. O., Herman, D., Papaioannou, A., Lau, A. N., & Adachi, J. D. (2021) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s282606 · Cited by 84
Osteoporosis Is More Prevalent in Adrenal than in Pituitary Cushing's Syndrome.
OHMORI, N., NOMURA, K., OHMORI, K., KATO, Y., ITOH, T., & TAKANO, K. (2003) · Endocrine Journal · doi:10.1507/endocrj.50.1 · Cited by 81
Glucocorticoid‐induced osteoporosis: lessons from Cushing's syndrome
Tóth, M., & Grossman, A. (2013) · Clinical Endocrinology · doi:10.1111/cen.12189 · Cited by 81
Mazziotti, G., Porcelli, T., Bianchi, A., Cimino, V, Patelli, I., Mejia, C., Fusco, A., Giampietro, A., De Marinis, L., & Giustina, A. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0125 · Cited by 68
Bone metabolism and mass in women with Cushing’s syndrome and adrenal incidentaloma
Francucci, C. M., Pantanetti, P., Garrapa, G. G., Massi, F., Arnaldi, G., & Mantero, F. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01602.x · Cited by 65
Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis
Hansen, K. E., Wilson, H. A., Zapalowski, C., Fink, H. A., Minisola, S., & Adler, R. A. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.362 · Cited by 65
Rangaswamaiah, S., Gangathimmaiah, V., Nordenstrom, A., & Falhammar, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00493 · Cited by 59
Osteoporosis and Fractures After Solid Organ Transplantation
Yu, T.-M., Lin, C.-L., Chang, S.-N., Sung, F.-C., Huang, S.-T., & Kao, C.-H. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.02.017 · Cited by 58
Livadas, S., & Bothou, C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00366 · Cited by 57
The osteoblastic niche in the context of multiple myeloma
Toscani, D., Bolzoni, M., Accardi, F., Aversa, F., & Giuliani, N. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12578 · Cited by 52
Glucocorticoid-induced osteoporosis
Silverman, S. L., & Lane, N. E. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0005-4 · Cited by 50
The pituitary–adrenal axis and body composition
Fernandez-Rodriguez, E., Stewart, P. M., & Cooper, M. S. (2009) · Pituitary · doi:10.1007/s11102-008-0098-2 · Cited by 49
When do the risks of repeated courses of corticosteroids exceed the risks of surgery?
Leung, R. M., Dinnie, K., & Smith, T. L. (2014) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21377 · Cited by 49
Cooper, M. S., Syddall, H. E., Fall, C. H. D., Wood, P. J., Stewart, P. M., Cooper, C., & Dennison, E. M. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02281.x · Cited by 48
Lan, G.-B., Xie, X.-B., Peng, L.-K., Liu, L., Song, L., & Dai, H.-L. (2015) · BioMed Research International · doi:10.1155/2015/413169 · Cited by 46
Möhlmann, J. E., Ezzafzafi, S., Lindemans, C. A., Jansen, M. H. A., Nierkens, S., Huitema, A. D. R., & van Luin, M. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01419-7 · Cited by 33
Metadata
- Authors
- Van Staa, T. P., Leufkens, H. G. M., & Cooper, C.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-03-01
- Volume
- 16
- Issue
- 3
- Pages
- 581-588
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2033830300
- Cited by
- 1,308
- References
- 57
- FWCI
- 68.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.